Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Therapeutic performance of recombinant antibodies relies on two independent mechanisms: antigen recognition and Fc-mediated antibody effector functions. Interaction of Fc-fragment with different FcR triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and determines longevity of the antibody in serum. In context of therapeutic antibodies FcγRs play the most important role. It has been demonstrated that the Fc-attached sugar moiety is essential for IgG effector functionality, dictates its affinity to individual FcγRs and determines binding to different receptor classes: activating or inhibitory. In this study, we systematically analyze effector functions of monoclonal IgG1 and its eight enzymatically engineered glycosylation variants. The analysis of interaction of glycovariants with FcRs was performed for single, as well as for antigen-bound antibodies and IgGs in a form of immune complex. In addition to functional properties we addressed impact of glycosylation on the structural properties of the tested glycovariants. We demonstrate a clear impact of glycosylation pattern on antibody stability and interaction with different FcγRs. Consistent with previous reports, deglycosylated antibodies failed to bind all Fcγ-receptors, with the exception of high affinity FcγRI. The FcγRII and FcγRIIIa binding activity of IgG1 was observed to depend on the galactosylation level, and hypergalactosylated antibodies demonstrated increased receptor interaction. Sialylation did not decrease the FcγR binding of the tested IgGs; in contrast, sialylation of antibodies improved binding to FcγRIIa and IIb. We demonstrate that glycosylation influences to some extent IgG1 interaction with FcRn. However, independent of glycosylation pattern the interaction of IgG1 with a soluble monomeric target surprisingly resulted in an impaired receptor binding. Here, we demonstrate, that immune complexes (IC), induced by multimeric ligand, compensated for the decreased affinity of target bound antibody towards FcRs, showing the importance of the IC-formation for the FcR- mediated effector functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“More recently, Dashivets et al. studied enzymatically engineered glycosylation variants and showed that deglycosylated IgG1 had a slightly diminished binding to FcRn, with digalactosylated IgG demonstrating superior binding than monogalactosylated and agalactosylated variants (87).”
From Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy (2017) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · cited 1×
“[12,65,92] Interaction of the FcRn with IgGs was reported to be independent of the antibody oligosaccharide pattern.”
BackgroundScott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754 · cited 1×
“[85] Sialylated antibodies are believed to be the pro-active species in IVIG (Intravenous Immune Globulin), which suppresses autoantibodymediated inflammation by activating the inhibitory FcγRIIb and downstream negative signaling pathways.”
BackgroundBruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery
Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., et al. (2001) · SLAS Discovery · doi:10.1177/108705710100600609 · Cited by 893
Thermofluor-based high-throughput stability optimization of proteins for structural studies
Ericsson, U. B., Hallberg, B. M., DeTitta, G. T., Dekker, N., & Nordlund, P. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.07.027 · Cited by 839
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 1×
“More than 40 therapeutic mAbs and mAb fragments are approved and prescribed today [1,2], the majority being of the IgG isotype.[3] The IgG molecule consists of two light chains (two domains each) and two heavy chains (four domains each).”
BackgroundKrapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674 · cited 1×
“[84] Impact of terminal sialic acid on the functionality of antibodies remains a controversial issue.”
Background
Research works printed but not linked: 27
- Kapur R, Einarsdottir HK, Vidarsson G. IgG-effector functions: "The Good, The Bad and The Ugly". Immunol Lett 2014 2 1. 24495619
- Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012 4; 1253: 170– 80. 10.1111/j.1749-6632.2011.06305.x 22288459 · DOI · Paper page
- Hogarth PM, Pietersz GA. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 2012 4; 11(4): 311– 31. 10.1038/nrd2909 22460124 · DOI · Paper page
- Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, et al Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011 2; 10(2): 101– 11. 10.1038/nrd3365 21283105 · DOI · Paper page
- Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 2009 3; 8(3): 226– 34. 10.1038/nrd2804 19247305 · DOI · Paper page
- Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 8 4; 313(5787): 670– 3. 16888140 · DOI · Paper page
- Huang W, Giddens J, Fan SQ, Toonstra C, Wang LX. Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. J Am Chem Soc 2012 7 25; 134(29): 12308– 18. 10.1021/ja3051266 22747414 PMC3427744 · DOI · Paper page
- Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008 8; 20(4): 471– 8. 10.1016/j.coi.2008.06.007 18606225 · DOI · Paper page
- Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, et al The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 2000 8; 37(12–13): 697– 706. 11275255 · DOI · Paper page
- Buck PM, Kumar S, Singh SK. Consequences of glycan truncation on Fc structural integrity. MAbs 2013 11; 5(6): 904– 16. 10.4161/mabs.26453 24492344 PMC3896604 · DOI
- Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J 2011 1; 6(1): 38– 44. 10.1002/biot.201000091 20949542 · DOI · Paper page
- Bohm S, Schwab I, Lux A, Nimmerjahn F. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Semin Immunopathol 2012 5; 34(3): 443– 53. 10.1007/s00281-012-0308-x 22437760 · DOI
- Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 8 4; 313(5787): 670– 3. 16888140 · DOI · Paper page
- Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci 2012 4; 1253: 170– 80. 10.1111/j.1749-6632.2011.06305.x 22288459 · DOI · Paper page
- Jefferis R. The glycosylation of antibody molecules: functional significance. Glycoconj J 1993 10; 10(5): 358– 61. 8298303
- Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012 10 15; 526(2): 159– 66. 10.1016/j.abb.2012.03.021 22465822 · DOI · Paper page
- Buck PM, Kumar S, Singh SK. Consequences of glycan truncation on Fc structural integrity. MAbs 2013 11; 5(6): 904– 16. 10.4161/mabs.26453 24492344 PMC3896604 · DOI
- Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012 10 15; 526(2): 159– 66. 10.1016/j.abb.2012.03.021 22465822 · DOI · Paper page
- Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J 2011 1; 6(1): 38– 44. 10.1002/biot.201000091 20949542 · DOI · Paper page
- Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, et al The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol 2000 8; 37(12–13): 697– 706. 11275255 · DOI · Paper page
- Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008 8; 20(4): 471– 8. 10.1016/j.coi.2008.06.007 18606225 · DOI · Paper page
- Zheng K, Bantog C, Bayer R. The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 2011 11; 3(6): 568– 76. 10.4161/mabs.3.6.17922 22123061 PMC3242843 · DOI · Paper page
- Houde D, Peng Y, Berkowitz SA, Engen JR. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 2010 8; 9(8): 1716– 28. 10.1074/mcp.M900540-MCP200 20103567 PMC2938052 · DOI · Paper page
- Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006 8 4; 313(5787): 670– 3. 16888140 · DOI · Paper page
- Lux A, Yu X, Scanlan CN, Nimmerjahn F. Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs. J Immunol 2013 4 15; 190(8): 4315– 23. 10.4049/jimmunol.1200501 23509345 · DOI · Paper page
- Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007 9; 7(9): 715– 25. 17703228 · DOI · Paper page
- Leabman MK, Meng YG, Kelley RF, DeForge LE, Cowan KJ, Iyer S. Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys. MAbs 2013 11; 5(6): 896– 903. 10.4161/mabs.26436 24492343 PMC3896603 · DOI · Paper page
Cited by
Pereira, N. A., Chan, K. F., Lin, P. C., & Song, Z. (2018) · mAbs · doi:10.1080/19420862.2018.1466767 · Cited by 334
“Mutations in the CH2 domain that destroyed the conserved N-glycosylation motif and hence gave rise to aglycosylated Fc resulted in complete loss of binding to most FcgRs except FcgRI.(11) Several approaches have been utilized to increase the affinity between antibody and the FcgRIII.”
BackgroundMethodAffinity of human IgG subclasses to mouse Fc gamma receptors
Dekkers, G., Bentlage, A. E. H., Stegmann, T. C., Howie, H. L., Lissenberg-Thunnissen, S., Zimring, J., Rispens, T., & Vidarsson, G. (2017) · mAbs · doi:10.1080/19420862.2017.1323159 · Cited by 293
Peschke, B., Keller, C. W., Weber, P., Quast, I., & Lünemann, J. D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00646 · Cited by 219
“Two studies reported that Fc-galactosylation results in a slight, albeit not statistically significant increase in FcγRIIIa-binding affinity and ADCC activity (16, 17).”
BackgroundFc Glycan-Mediated Regulation of Placental Antibody Transfer
Jennewein, M. F., Goldfarb, I., Dolatshahi, S., Cosgrove, C., Noelette, F. J., Krykbaeva, M., Das, J., Sarkar, A., Gorman, M. J., Fischinger, S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.044 · Cited by 212
“Fc-Galactosylation Affects Antibody Binding to FcRn and Other Fc Receptors Contradictory roles for Fc glycosylation on FcRn binding have been reported (Bakchoul et al., 2013; Dashivets et al., 2015; Einarsdottir et al., 2013; Jansen et al., 2016b; Jefferis, 2012), including reports documenting negligible effects of Fc…”
BackgroundInfluentialWilcox, C. R., Holder, B., & Jones, C. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01294 · Cited by 200
“studied enzymatically engineered glycosylation variants and showed that deglycosylated IgG1 had a slightly diminished binding to FcRn, with digalactosylated IgG demonstrating superior binding than monogalactosylated and agalactosylated variants (87).”
Metadata
- Authors
- Dashivets, T., Thomann, M., Rueger, P., Knaupp, A., Buchner, J., & Schlothauer, T.
- Affiliations
- Center for Integrated Protein Science Munich (DE)
- Roche Pharma AG (Germany) (DE)
- Corresponding author
- Schlothauer, Tilman
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-12-11
- Volume
- 10
- Issue
- 12
- Pages
- e0143520
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4676693
- OpenAlex
- W2190603070
- Cited by
- 101
- References
- 69
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 8 · 2023: 12 · 2022: 7 · 2021: 13 · 2020: 12 · 2019: 10 · 2018: 8 · 2017: 14 · 2016: 7 · 2015: 1
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Roche Innovation Center Zurich
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- IgG glycosylation, Fc gamma receptor, antibody effector functions, therapeutic monoclonal antibodies, FcγRI, FcγRIIa, FcγRIIB, FcγRIIIa, neonatal Fc receptor, galactosylation, sialylation, deglycosylation, immune complexes, antibody stability, antibody structure, antibody-drug conjugates
- MeSH terms
- Antibodies, Monoclonal, Antibody Affinity, Antigen-Antibody Complex, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Galactose, Glycosylation, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Molecular Sequence Data, Protein Binding, Recombinant Proteins, Sialic Acids, Protein Engineering, Gene Expression, Receptors, IgG, Surface Plasmon Resonance, Protein Stability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.